Register for our free email digests:
Division of Abzena Ltd./PolyTherics Ltd.
Latest From BioWest Therapeutics Inc.
Ritter Pharmaceuticals, Inc. has appointed AnnKatrin Petersen-Jappelli chief medical officer (CMO). Petersen-Jappelli, who is currently on the board of Salgomed Inc., brings 25 years of drug development experience to Ritter and was previously advisor, scientific research and clinical development leader of a Phase III program at Santarus Inc. Prior to this, she was vice-president of product development at MIGENIX Inc. and has held development positions at Pfizer, Sandoz (Novartis) and Agouron Pharmaceuticals.
Infection with the hepatitis C virus (HCV) represents an important healthcare problem worldwide. Current estimates suggest that globally about 170 million people, representing approximately 3% of the world's population, are chronically infected, and are at risk of developing liver cirrhosis and/or hepatocellular carcinoma. Estimates indicate that in the US, three to four million people are infected annually. The prevalence of HCV-related disease is increasing, but no vaccine is yet available.
- Large Molecule
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Abzena Ltd.
- Senior Management
Matthew Baker, PhD, CEO & CSO
Neil Butt, PhD, VP, Bus. Dev.
- Contact Info
Phone: (0) 1223 496190
Babraham Research Campus
Cambridge, CB22 3AT
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.